Overview of Regunac-DR

Quick Facts

Property	Description
Active ingredient	Diclofenac (Sodium or Potassium)
Form	Oral Tablet or Capsule
Pharmacological class	Nonsteroidal Anti-Inflammatory Drug (NSAID)
Common use	Relief of pain and inflammation
Origin	Synthetic, Phenylacetic Acid Derivative

Overview: What is Regunac-DR and its Core Classification?

Regunac-DR is a pharmaceutical preparation containing the active component Diclofenac, a synthetic compound classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). It is a single-ingredient product belonging specifically to the phenylacetic acid class, a category distinguished by its chemical structure. The active ingredient, Diclofenac, is clinically recognized for its potent analgesic and anti-inflammatory properties. This drug’s classification fundamentally defines its therapeutic role as an agent that manages both pain and underlying inflammation.

Composition and the Role of Delayed-Release (DR) Formulation

Regunac-DR is formulated for oral administration as a tablet or capsule and is defined by its distinctive delayed-release (DR) design. This preparation utilizes a specialized enteric coating that prevents the drug from dissolving rapidly in the acidic environment of the stomach. This design is intended to deliver the Diclofenac safely to the small intestine for optimal absorption. The delayed-release characteristic is a key differentiating factor, as it is specifically positioned for individuals requiring the sustained effect of the drug while potentially improving gastric tolerance.

The General Purpose: Pain, Inflammation, and Fever

The general purpose of Regunac-DR is to act as a dual-action analgesic and anti-inflammatory agent. Its function is primarily achieved by suppressing prostaglandin production, which helps to relieve the discomfort associated with general pain, reduce swelling, and address stiffness. Furthermore, this drug exhibits antipyretic effects, which means it can also help to reduce fever, a property associated with the substance.

What side effects are possible with Regunac-DR?

Possible Side Effects and Safety Information

The safety profile for Regunac-DR, as documented by government regulatory authorities, is structured around critical safety categories, including major system-organ class risks, dose-related patterns, and population-specific restrictions.

Serious Adverse Reactions

Official regulatory documents emphasize the potential for serious, potentially fatal adverse reactions, particularly involving the cardiovascular and gastrointestinal systems:

Cardiovascular Thrombotic Events: An increased risk of serious cardiovascular events, such as myocardial infarction (heart attack) and stroke, has been observed. This risk may begin early in treatment and is consistently noted to increase with higher doses and longer duration of use.
Serious Gastrointestinal Events: This includes inflammation, bleeding, ulceration, or perforation of the stomach or intestines, which can occur at any time without warning symptoms and may be fatal.
Hepatotoxicity and Nephrotoxicity: Liver failure and kidney damage are documented risks. Liver enzymes should be monitored, and use is generally cautioned in patients with impaired hepatic or renal function.
Serious Skin Reactions: Rare, severe skin reactions, such as Stevens-Johnson syndrome and Toxic Epidermal Necrolysis, have been reported.

Common and Other Adverse Reactions

Adverse reactions reported across various system-organ classes, often classified as common, include headache, dizziness, nausea, vomiting, indigestion (dyspepsia), diarrhea, constipation, and abdominal pain.

Safety Restrictions and Contraindications

The use of Regunac-DR is restricted in specific patient populations, based on documented risk:

Cardiovascular Restrictions: The medicine is contraindicated for the relief of pain right before or after coronary artery bypass graft (CABG) surgery and in patients with established congestive heart failure (NYHA Class II-IV), ischemic heart disease, or cerebrovascular disease.
Allergic Reactions: It is contraindicated in patients who have experienced asthma, hives (urticaria), or other allergic-type reactions after taking aspirin or other non-steroidal anti-inflammatory drugs (NSAIDs).
Pregnancy: It is contraindicated during the third trimester of pregnancy.

Official safety recommendations stress the use of the lowest effective dose for the shortest duration necessary to minimize the risk of serious side effects.

Overdose and Emergency Response

Overdose and when to seek help

An overdose of Regunac-DR is classified as a serious event defined by potential toxicity to multiple physiological systems, based on official prescribing information.

Documented Overdose Manifestations

Common signs of overdose documented by regulatory authorities primarily include gastrointestinal effects such as Epigastric Pain, Nausea, and Vomiting, alongside Central Nervous System (CNS) Effects like Drowsiness, Headache, Tinnitus, and Dizziness. Reduced urine output (oliguria) is also a documented manifestation.

Serious and Life-Threatening Outcomes

A large overdose can lead to severe or life-threatening outcomes. The documented potential for serious complications includes Acute Renal Failure, severe Hepatotoxicity (liver damage), Gastrointestinal Hemorrhage, and severe CNS events such as Seizures or Coma. Regulatory documents note that elderly patients and those with pre-existing hepatic or renal impairment are at a greater documented risk of severe complications.

Immediate Emergency Action Required

The official regulatory guidance is to Seek medical help right away if an overdose is suspected. Due to the risk of severe organ damage, emergency medical help must be sought immediately if severe symptoms such as seizures or heavy bleeding occur. Management is symptomatic and supportive as No specific antidote is known. Hospital observation is required for intensive monitoring of vital and organ function, particularly renal and hepatic function.

Therapeutic Uses of Regunac-DR

What Regunac-DR Treats: Main Uses and Benefits

Regunac-DR is a medication that provides supportive relief across multiple therapeutic domains, primarily addressing symptoms related to inflammatory or irritative states and physical discomfort. It is commonly used to address signs and symptoms associated with chronic joint conditions, including Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis.

The delayed-release formulation is relevant for managing symptoms that require a sustained effect, contributing to easing the overall symptomatic burden in long-term conditions. It is also applied in conditions marked by heightened, recurrent symptoms that disrupt daily stability, such as the pain and cramping of Primary Dysmenorrhea and the discomfort of acute migraine attacks. Furthermore, it helps manage symptomatic discomfort in clinical scenarios that involve acute pain flares, post-injury inflammation, and trauma-related swelling.

“This medication assists with maintaining functional stability and supports the patient during difficult episodes by easing distress.”

Quick Facts: Therapeutic Benefit

Domain	Symptom Axis	Benefit
Chronic	Pain, Swelling, Stiffness	Supports sustained symptom stability
Acute	Acute Pain Flares, Trauma-related Swelling	Contributes to improved comfort
Episodic	Recurrent Discomfort, Functional Strain	Assists with temporary symptom stabilization

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who can and cannot use Regunac-DR?

Regunac-DR (Diclofenac) eligibility is strictly defined by regulatory authorities and is determined by patient history, specific comorbidities, and life stage. Only the adult population that is free of absolute contraindications is eligible for standard use.

Absolute Contraindications

Use is strictly prohibited in patients with a history of allergic reactions (like asthma or hives) to aspirin or other NSAIDs, active gastrointestinal bleeding or ulcers, or severe organ impairment (severe renal or hepatic failure). The medicine is also contraindicated for the treatment of pain following Coronary Artery Bypass Graft (CABG) surgery and in patients with established severe heart failure (NYHA class II-IV) or other established cardiovascular diseases.

Age and Physiological Restrictions

Regunac-DR is not recommended for children and adolescents generally under 14 or 16 years of age, as dosage strengths are often considered unsuitable. Use is contraindicated during the third trimester of pregnancy and must generally be avoided after 20 weeks of gestation. Use is not generally recommended while breastfeeding.

Older adults and patients with mild-to-moderate renal or hepatic impairment must use the medicine with caution and may require closer medical surveillance, as specified in the official labeling.

What should I know about interactions with other medicines?

Regunac-DR Interactions with other medicines and products

This section details officially documented interactions for Regunac-DR (Diclofenac), based strictly on government regulatory information.

Contraindicated Combinations

Co-administration is formally prohibited with other systemic Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), including Aspirin at anti-inflammatory doses. This is due to a documented, significantly increased risk of serious gastrointestinal adverse events. Use is also prohibited for peri-operative pain in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Documented Interactions and Resulting Risk

Interacting Product Category	Official Interaction Constraint
Anticoagulants/Antiplatelet Agents	Documented increased risk of serious bleeding (e.g., GI hemorrhage).
Antihypertensives (ACE inhibitors/ARBs)	May diminish the therapeutic effect and increase the risk of renal impairment.
Lithium, Digoxin, Methotrexate	Documented to increase plasma concentrations of these co-administered medicines.
CYP2C9 Inhibitors (e.g., Voriconazole)	Official finding that these agents increase Diclofenac plasma exposure.
Alcohol	Concomitant consumption is officially documented to increase the risk of gastrointestinal bleeding.

Population-Specific Note

Regulatory documentation specifies that the elderly are at a heightened risk for experiencing severe adverse effects from documented interactions, particularly those involving the gastrointestinal system and renal function.

Mechanism of Action

Inhibition of Prostaglandin Synthesis via COX Enzymes

The primary mechanism involves the non-selective, competitive inhibition of both Cyclooxygenase-1 (COX-1) and Cyclooxygenase-2 (COX-2) enzymes. By blocking the active sites, the drug prevents the conversion of arachidonic acid into prostaglandins, which are powerful molecular drivers of inflammation and pyresis.

Modulation of Nociceptive and Thermoregulatory Signaling

The systemic reduction in prostaglandins, particularly PGE2, modifies two core physiological systems simultaneously. Peripherally, it limits the excessive sensitization of pain receptors (nociceptors), which reduces peripheral nociceptor sensitization. Centrally, this molecular suppression acts within the hypothalamus, facilitating the re-establishment of the normal thermal set-point.

Mechanistic Scope and Limitations

The drug's mechanism is fundamentally constrained to processes mediated by prostaglandins and does not operate in pathways independent of COX enzymes. Furthermore, the non-selective action profile is a mechanistic reality that extends its influence to homeostatic functions regulated by constitutive prostaglandins.

Dosage and Administration Information

How to Use Regunac-DR

Regunac-DR is administered orally as a delayed-release tablet. The usage protocol is designed to ensure the correct function of the specialized enteric coating and adherence to established dose limits.

The tablet must be swallowed whole with a full glass of water and must not be crushed, chewed, or divided, as this compromises the delayed-release mechanism. Intake may occur with or without food, as food delays the rate but not the extent of overall drug absorption.

Standardized Dosing and Frequency

The total daily dosage is established for specific uses and is always administered in divided daily doses (e.g., twice or three times daily).

Indication	Typical Total Daily Dose
Osteoarthritis	100 mg to 150 mg per day
Rheumatoid Arthritis	150 mg to 200 mg per day
Ankylosing Spondylitis	100 mg to 125 mg per day

The overall use protocol emphasizes employing the lowest effective dose for the shortest duration consistent with treatment goals. This principle governs the length of treatment across all indications, from acute use to long-term chronic management.

Population-Specific Rules

For older adults, treatment is initiated using the lowest effective dosage to minimize potential risks. Dosing adjustment for the unchanged drug is generally not necessary for patients with mild to moderate renal dysfunction.

Recent Clinical Evidence

The research base for Regunac-DR and its active component has been studied extensively in conditions marked by functional limitations and fluctuating symptoms, such as Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. Evidence for these chronic uses includes Randomized Controlled Trials (RCTs), Systematic Reviews, and Meta-analyses. These studies explored patient-reported outcomes related to physical discomfort and daily functioning over defined time intervals. Findings describe patterns observed in changes to pain scores and measured functional outcomes.

Short-term RCTs have also examined the role of the drug in acute and episodic inflammatory pain, including Primary Dysmenorrhea and pain flares. Research focused on rapid symptomatic changes, assessing outcomes such as pain intensity and the need for rescue medication over brief observation periods (often 24 hours). The studies contribute to understanding symptom patterns during these acute episodes.

The distinctive delayed-release (DR) formulation has been assessed through Pharmacokinetic (PK) and Bioequivalence studies that explore drug absorption and release characteristics. These findings provide context on the formulation but do not directly address long-term patient-reported outcomes relative to other forms of the same drug.

The overall evidence landscape has consistent limitations. Core efficacy trials for chronic conditions typically have follow-up durations that were limited to around three months, meaning long-term effects are not fully established. Data for certain groups remain insufficient, including specific populations defined by complex comorbidities, and robust comparative evidence between the DR and immediate-release versions is lacking.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Regunac-DR (FAQ)

Q: Is Regunac-DR safe to take with food, or does it need to be taken on an empty stomach?

Regulatory product information notes that Regunac-DR may be taken with food, milk, or antacids, which may help to mitigate potential stomach upset. However, consuming it with food may slightly delay the time it takes for the drug to start relieving pain by slowing down the absorption process.

Q: What are the most common side effects to look out for when taking Regunac-DR?

According to regulatory documents, the most commonly reported side effects include gastrointestinal issues such as upset stomach, nausea, diarrhea, stomach pain, indigestion (dyspepsia), and gas. Other common effects include headache.

Q: Is Regunac-DR safe for use in older adults (e.g., over 65)?

Official information specifies that older adults are generally at a greater risk for experiencing serious side effects, particularly gastrointestinal bleeding and kidney problems. Due to this increased risk, official safety documentation emphasizes using the lowest effective dose for the shortest possible duration.

Q: What should I know about taking Regunac-DR with alcohol?

Regulatory documents list alcohol consumption as a factor that can increase the risk of serious gastrointestinal events, including bleeding and ulcers, while taking this medicine. Regulatory documents state that patients should be aware of this risk when considering alcohol consumption while taking Regunac-DR.

Q: Can Regunac-DR cause stomach issues or bleeding?

Yes, the medicine carries a Boxed Warning regarding the potential for serious gastrointestinal adverse events. These events include inflammation, bleeding, ulceration, and perforation of the stomach or intestines, which can occur at any time during use and may be fatal.

Q: Should Regunac-DR be used for children or adolescents?

Studies supporting the safety and effectiveness of this specific delayed-release formulation have not been established in pediatric patients (children and adolescents). For this reason, the approved indications for this product are limited to use in adults.

Q: Are there any specific storage requirements for Regunac-DR?

Official product information requires the tablets to be stored at controlled room temperature (e.g., 20 C to 25 C or 68 F to 77 F). As with all medicines, it should be maintained out of the sight and reach of children.

Q: If I have kidney problems, is Regunac-DR still an option?

According to regulatory warnings, NSAIDs can cause renal toxicity (kidney damage). The medicine should be avoided in patients with advanced kidney disease unless the potential benefits significantly outweigh the risks. Patients with existing kidney impairment require closer monitoring of their kidney function during treatment.

Q: Can Regunac-DR affect my heart or blood pressure?

Yes, this medicine carries a Boxed Warning because official data shows an increased risk of serious cardiovascular thrombotic events, including heart attack and stroke. Additionally, the medicine can cause the onset of new high blood pressure or worsen existing hypertension.

Q: Can I drive or operate machinery while taking Regunac-DR?

The official label includes potential side effects such as dizziness, drowsiness, and visual disturbances. Because of these potential effects, regulatory information suggests awareness is appropriate when driving or operating complex machinery.

Q: How is Regunac-DR related to other types of pain relievers, like ibuprofen or naproxen?

Regunac-DR is chemically related to ibuprofen and naproxen as they all belong to the same broad class of medicines, known as Nonsteroidal Anti-Inflammatory Drugs (NSAIDs). This classification defines its mechanism of action against pain and inflammation.

Q: Is Regunac-DR safe to take during pregnancy or while breastfeeding?

Regulatory warnings indicate the medicine should be avoided in pregnant women starting at 30 weeks gestation due to the serious risk of harm to the fetus. Regarding breastfeeding, studies indicate only negligible amounts of the active ingredient pass into breast milk, and official guidance notes that consulting a healthcare provider is appropriate.

Q: What other medicines should I avoid while taking Regunac-DR?

Official documents advise caution or avoidance when taking Regunac-DR with other NSAIDs (like ibuprofen), anticoagulants (blood thinners), and certain medicines used for blood pressure (such as ACE inhibitors or ARBs). Interactions are also noted with diuretics (water pills) and oral corticosteroids.

Q: What is the main reason Regunac-DR is prescribed?

According to the FDA and DailyMed, this medicine is approved to relieve the signs and symptoms associated with certain inflammatory conditions in adults. These conditions include Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis.

Q: Is Regunac-DR the same as regular Regunac?

No, Regunac-DR is a specific formulation designed with a delayed-release (DR) mechanism. This uses an enteric coating to prevent the tablet from dissolving in the stomach, ensuring the medicine is released later in the small intestine. This differs from immediate-release forms of the drug.

Q: How quickly does Regunac-DR start working?

Regulatory pharmacokinetic studies show that the drug reaches its highest concentration in the blood approximately 2 to 4 hours after a dose is taken. This time frame provides an indication of when the highest concentration of the medicine is typically reached in the bloodstream.

Q: Does Regunac-DR cause tiredness or fatigue?

Yes. Sleepiness (also known as somnolence or drowsiness) is listed in the official documents as one of the commonly reported side effects associated with the delayed-release tablets.

Q: What is the difference between Regunac-DR and similar medicines used for the same condition?

Regunac-DR is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID), just like many other common pain relievers. However, the oral form of Diclofenac is categorized as a prescription-only medicine due to its potency and established risk profile, which requires ongoing monitoring by a healthcare professional.

Q: What happens if I miss a scheduled time to take Regunac-DR?

Official patient guidelines indicate that if a dose is missed, the patient should skip that missed dose. The next scheduled dose should be taken at the usual time, without attempting to take two doses together to make up for the missed one.

Q: Is Regunac-DR habit-forming or addictive?

No. This medicine is a Nonsteroidal Anti-Inflammatory Drug (NSAID). According to governmental classifications, it is not listed as a controlled substance and is not considered to be habit-forming or addictive.

Q: Are there different strengths of Regunac-DR tablets available?

Yes, based on the official documentation, the delayed-release tablets are typically supplied in different strengths. These strengths include 25 mg, 50 mg, and 75 mg tablets.

Q: What should I do if a side effect seems serious?

The official product labeling indicates that if a patient experiences a suspected serious side effect, seeking emergency medical attention is necessary. Adverse reactions can also be reported directly to the regulatory agency (like the FDA) using the contact information provided in the Medication Guide.

Q: Is there a generic version of Regunac-DR available?

Yes, the active drug component in Regunac-DR, which is Diclofenac sodium delayed-release, is available for purchase as a generic drug.

Q: Why do some people say they have trouble sleeping after starting Regunac-DR?

Insomnia, or difficulty falling or staying asleep, is listed in official documentation as a possible, occasionally reported side effect associated with the use of the medicine.

Q: Is the Regunac-DR name related to any other drugs?

The active ingredient is the generic drug Diclofenac, which is used in many other branded and generic medicines worldwide. These related products may come in different salt forms or delivery types, such as immediate-release tablets or topical gels.

Q: Is Regunac-DR recommended for individuals with a history of seizures?

While convulsions (seizures) are listed as a rare adverse reaction in the official safety profile, this is an important factor for prescribers to consider. Official information suggests that patients with a history of seizures should discuss the specific risks with their healthcare provider.

Q: Are there any known interactions between Regunac-DR and common supplements like vitamins?

Official regulatory documents focus mainly on drug-to-drug interactions, and information is often limited regarding the safety of combining this medicine with herbal remedies or dietary supplements. Supplements are not tested under the same strict regulatory conditions as prescription drugs.

Q: Does Regunac-DR cause weight gain or weight loss?

Weight changes (either weight gain or weight loss) are listed in the official safety documents as an adverse experience that has been reported occasionally with the use of this medicine.

Q: Is Regunac-DR classified as a stimulant?

No. This medicine is classified as a Nonsteroidal Anti-Inflammatory Drug (NSAID). Its mechanism of action is related to managing pain and inflammation, and it is not categorized as a stimulant.

Q: How long do I have to wait to dispose of Regunac-DR after I stop taking it?

Regulatory disposal guidelines recommend that unused or expired medicine be disposed of as soon as possible once it is no longer needed. The recommended methods are those detailed in official instructions, such as using authorized drug take-back programs or following guidelines for mixing it with waste for home disposal. No specific waiting period is advised.

How should Regunac-DR be stored and disposed of?

Regunac-DR (diclofenac sodium delayed-release) must be stored according to regulatory specifications to ensure product stability and safety. The medication requires storage at controlled room temperature, specifically between 20^circC and 25^circC (68^circF and 77^circF). It must be kept in its original, tightly closed container and protected from light, moisture, and excessive heat. The labeling explicitly instructs users to keep the medicine out of the sight and reach of children and to avoid freezing. For disposal, unused or expired product must be discarded according to local regulations, ideally through an authorized drug take-back program. It should not be flushed down the toilet or poured into a drain.

Regunac-DR